TIDMYGEN
RNS Number : 1343X
Yourgene Health PLC
25 August 2022
Yourgene Health plc
("Yourgene", the "Company" or the "Group")
Notice of AGM, Change of Registered Address and
Investor Presentation
Manchester, UK - 25 August 2022: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that the
Notice of Annual General Meeting ("AGM") and Form of Proxy will
shortly be available on the Company's website at:
www.yourgene-health.com/investors/key-documents/shareholder-communications
and are being posted to those shareholders who have opted out of
electronic communications.
The majority of Yourgene shareholders receive electronic
communications as part of the Company's ESG programme. Yourgene is
writing to all remaining shareholders to ask them to do the same to
reduce paper usage and support the Company on its ESG
initiatives.
Change of registered office
Yourgene also announces that the Company's registered office
address has changed to: Skelton House, Lloyd Street North,
Manchester Science Park, Manchester M15 6SH with immediate
effect.
Notice of AGM and Investor presentation
The Company's AGM will be held at 2:00pm (BST) on Tuesday 27
September 2022, and will be held as a hybrid meeting
electronically, via the Investor Meet Company platform ("IMC") and
physically, at the Company's new offices Skelton House, Lloyd
Street North, Manchester Science Park, Manchester M15 6SH.
The Company's CEO, Lyn Rees, will also provide shareholders with
a short presentation after the formal business of the AGM concludes
and there will be an opportunity for investors to ask questions.
Investors can sign up to IMC for free and add to meet Yourgene
Health plc via:
https://www.investormeetcompany.com/yourgene-health-plc/register-investor
Shareholders taking part via the IMC platform will not be able
to speak or vote on the AGM resolutions. Shareholders are therefore
strongly encouraged to exercise their voting rights by completing
and submitting a Form of Proxy. It is highly recommended that
Shareholders submit their Form of Proxy as early as possible to
ensure that their votes are counted at the AGM. Shareholders are
strongly encouraged to appoint the Chairman as your proxy to ensure
that each Shareholder's vote will be counted in the event of
restrictions on shareholders and proxies attending the AGM in
person.
If you wish to submit a proxy vote for this meeting, please
submit your vote online at www.signalshares.com. For your vote to
be valid please ensure that it is received by no later than 2:00pm
(BST) on Friday 23 September 2022. Alternatively, should you wish
to vote via the CREST system, please see the instructions in the
Notice of Meeting.
If you wish to attend the AGM in your capacity as a shareholder,
please bring proof of shareholding or if shares are held through a
nominee account, a letter of representation, to facilitate your
entry to the Meeting. Any shareholder wishing to attend in person
must register in advance by contacting the Company at
yourgene@walbrookpr.com .
Open Day
As previously announced on 16 August 2022, the Company is
hosting an Open Day, immediately after the AGM, at its new
facilities at Manchester Science Park, on Tuesday 27 September 2022
from 3:00pm to 6:00pm (BST), welcoming shareholders, analysts and
other interested stakeholders.
All Open Day attendees must register through Walbrook PR to
reserve a space. For more information and to
register, please email yourgene@walbrookpr.com or telephone Walbrook PR on +44 (0)20 7933 8780.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Singer Capital Markets (Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Lianne Applegarth / Alice Woodings Mob: 07584 391 303 / 07407 804 654
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops integrated genomic technologies and services
enabling precision medicine. The group works in partnership with
global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The Yourgene Genomic Services team works with healthcare
professionals, researchers and pharmaceutical organisations to
support and accelerate scientific advances in genomic medicine. The
division's specialist services guide decisions about abnormalities,
hereditary risk and treatment in addition to providing novel
insights in research and discovery. Accredited clinical services
are provided in Oncology and Reproductive Health within the UK and
worldwide. The team of scientific experts offer consultative
services to help guide partners in selecting the right technology
and approach for their applications.
In August 2020, Yourgene acquired Coastal Genomics , Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSEEFMLEESEEA
(END) Dow Jones Newswires
August 25, 2022 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024